Summary:
[unable to retrieve full-text content]CoinspeakerJohnson & Johnson Reports Better than Expected Q2 2023 Earnings, JNJ Shares Up Slightly The pharmaceutical segment reported the highest sales with about .71 billion, followed by MedTech with a total sales of about .78 billion, and the remaining accrued from the consumer health segment. Johnson & Johnson Reports Better than Expected Q2 2023 Earnings, JNJ Shares Up Slightly
Topics:
Steve Muchoki considers the following as important: Business News, jnj, jnj stock, johnson & johnson stock, Market News, News, Stocks, Wall Street
This could be interesting, too:
[unable to retrieve full-text content]CoinspeakerJohnson & Johnson Reports Better than Expected Q2 2023 Earnings, JNJ Shares Up Slightly The pharmaceutical segment reported the highest sales with about .71 billion, followed by MedTech with a total sales of about .78 billion, and the remaining accrued from the consumer health segment. Johnson & Johnson Reports Better than Expected Q2 2023 Earnings, JNJ Shares Up Slightly
Topics:
Steve Muchoki considers the following as important: Business News, jnj, jnj stock, johnson & johnson stock, Market News, News, Stocks, Wall Street
This could be interesting, too:
Chimamanda U. Martha writes European Banking Giant BNP Paribas Reports Exposure to Bitcoin ETF
Mayowa Adebajo writes Senator Lummis Challenges Government’s Stance on Crypto
Bhushan Akolkar writes Ethereum Network Growth Hits One-Year High, ETH Price to Follow Soon?
Godfrey Benjamin writes Top Solana Developer Shares Key Network Update
Coinspeaker
Johnson & Johnson Reports Better than Expected Q2 2023 Earnings, JNJ Shares Up Slightly
The pharmaceutical segment reported the highest sales with about $13.71 billion, followed by MedTech with a total sales of about $7.78 billion, and the remaining accrued from the consumer health segment.
Johnson & Johnson Reports Better than Expected Q2 2023 Earnings, JNJ Shares Up Slightly